M. Hayashi et al., Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction, J AM COL C, 37(7), 2001, pp. 1820-1826
Citations number
31
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
OBJECTIVES The study evaluates the effect of atrial natriuretic peptide (AN
P) compared with nitroglycerin (GTN) on left ventricular (LV) remodeling af
ter first anterior acute myocardial infarction (AMI).
BACKGROUND Compared with GTN, ANP suppresses the renin-angiotensin-aldoster
one system and endothelin-1 (ET-1), which stimulate LV remodeling.
METHODS Sixty patients with a first anterior AMI were randomly divided into
the ANP (n = 30) or GTN (n = 30) groups after direct percutaneous translum
inal coronary angioplasty. We evaluated LV ejection fraction (LVEF), end-di
astolic volume index (LVEDVI) and endsystolic volume index (LVESVI) at the
acute phase and after one month. We also measured neurohumoral factors duri
ng study drug infusion.
RESULTS There nas no difference in the baseline characteristics or LVEF (46
.9 +/- 1.0 vs. 46.8 +/- 1.3%) between the two groups. Although there was no
difference in hemodynamics during the infusion periods, the LVEF tvas sign
ificantly improved after one month compared with the baseline value in both
groups, but it was improved more in the ANP group than in the GTN group (5
4.6 +/- 1.1%, 50.8 +/- 1.3%, p < 0.05). Left ventricular enlargement was pr
evented in the ANP group (LVEDVI, 85.8 +/- 3.1 ml/m(2) to 87.3 +/- 2.7 ml/m
(2); p = ns, LVESVI, 45.6 +/- 1.8 ml/m(2) to 41.0 +/- 2.1 ml/m(2), p < 0.05
) but not in the GTN group (LVEDVI, 86.2 +/- 4.1 to 100.2 +/- 3.7, p < 0.01
; LVESVI, 46.3 +/- 2.8 ml/m(2) to 51.1 +/- 3.0 ml/m(2), p = ns). During the
infusion, ANP suppressed plasma levels of aldosterone, angiotensin II and
ET-1 compared with GTN.
CONCLUSIONS These findings indicate that in patients with a first anterior
AMI, an ANP infusion can prevent LV remodeling better than can GTN, and eff
ectively suppresses aldosterone, angiotensin II and ET-1. (J Am Coll Cardio
l 2001;37:1820-6) (C) 2001 by the American College of Cardiology.